BioNanomatrix nanoAnalyzer 1000 System to be introduced at ASHG Annual Meeting

NewsGuard 100/100 Score

BioNanomatrix, Inc., which is developing and commercializing breakthrough single-molecule genomic analysis technology, will introduce next month the nanoAnalyzer 1000 System at the American Society of Human Genetics (ASHG) Annual Meeting from November 2-6, 2010 in Washington, D.C.

The nanoAnalyzer 1000 System is intended for advanced analyses of DNA and other macromolecules and consists of a disposable nanochannel silicon-based device, analytical instrumentation, software and reagents.  The system is currently being tested in collaboration with leading researchers in the genomics field.

"This event is the culmination of several years of effort to develop a complete system for state-of-the-art analyses of DNA and potentially other large molecules of biological interest," said Edward L. Erickson, BioNanomatrix's president and chief executive officer.  "We expect to make the nanoAnalyzer 1000 System available to early access customers following the New Year."

The company further announced that it is developing a wide range of applications for the nanoAnalyzer 1000 System, including:

  • Assessment of DNA sample quality for advanced sequencing and other genomic analysis methods;
  • Assessment of DNA damage induced by environmental factors such as ionizing radiation and pollutants;
  • Adjunctive methods for assisting researchers in genome assembly, assembly validation, finishing and scaffolding; and
  • Identification and analysis of structural variations in genomic DNA.

The nanoAnalyzer 1000 System on display at Booth #723 at ASHG, which is being held at the Walter E. Washington Convention Center in Washington, D.C.  

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Baylor study reveals role of newly inherited DNA variants in recessive diseases